Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

merck.com

Total trials

65

Active

0

Phase 3

24

Total enrollment

21,231

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 0 of 0 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal

Next readouts

No upcoming readouts found.

Top conditions

  • Constipation6
  • Bowel Dysfunction5
  • Ileus5
  • Opioid-Induced Constipation4
  • Renal Impairment3
  • Clostridium Difficile Infection3
  • Bacteremia2
  • Cancer2

Frequently asked questions about Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

How many clinical trials does Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) have on ClinicalTrials.gov?
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) is listed as the lead sponsor on 65 clinical trials in ClinicalTrials.gov, 0 of which are currently active (recruiting, enrolling, or ongoing).
How many of Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'s trials are in Phase 3?
24 of Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'s trials are in Phase 3.
What therapeutic areas does Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) focus on?
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'s most-studied conditions on ClinicalTrials.gov are Constipation, Bowel Dysfunction, Ileus, Opioid-Induced Constipation, Renal Impairment.